Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
暂无分享,去创建一个
S. Papish | P. Fox | F. Holmes | J. O’Shaughnessy | B. Hellerstedt | S. Peck | S. Vukelja | R. Collea | L. Asmar | R. Resta | Yunfei Wang | L. Krekow | Shrinivas Diggikar | Praveen K Reddy | Shrinivas M Diggikar
[1] R. Greil,et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] P. Lønning,et al. Interpreting plasma estrogen levels in breast cancer: caution needed. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Banerjee,et al. Predictors of recovery of ovarian function during aromatase inhibitor therapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] M. Climent,et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] M. Dowsett,et al. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Kreienberg,et al. Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle , 2012, Breast Cancer Research and Treatment.
[7] G. Greendale,et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women's Health Across the Nation (SWAN) , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] P. Neven,et al. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor , 2011, Menopause.
[9] R. Greil,et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Kelley,et al. Evidence for drugs and biomarkers in oncology guidelines (GLs): A survey of the National Comprehensive Cancer Network (NCCN) colon cancer panel. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Rugo,et al. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. , 2011, Cancer treatment reviews.
[12] Richard A. Anderson,et al. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. , 2011, The Journal of clinical endocrinology and metabolism.
[13] V. Valero,et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Griggs,et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Singletary,et al. Incidence and time course of bleeding after long‐term amenorrhea after breast cancer treatment , 2010, Cancer.
[16] E. Perez,et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.
[17] A. DeMichele,et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors , 2010, Cancer.
[18] Yusuke Nakamura,et al. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration , 2009, World journal of surgical oncology.
[19] B. Nan,et al. Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. , 2008, The Journal of clinical endocrinology and metabolism.
[20] D. Ziegler,et al. Erratum to ‘Clinical use of aromatase inhibitors (AI) in premenopausal women’ [J. Steroid Biochem. Mol. Biol. 95 (2005) 121–127] , 2008, The Journal of Steroid Biochemistry and Molecular Biology.
[21] J. Cauley,et al. Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women , 2008 .
[22] K. Blackwell,et al. A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer , 2008, Cancer investigation.
[23] M. Ellis,et al. Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines , 2007 .
[24] C. Hudis,et al. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. , 2006, Clinical breast cancer.
[25] S. Nakajima,et al. Resumption of Menses with Initiation of Letrozole After Five Years of Amenorrhea on Tamoxifen: Caution Needed When Using Tamoxifen Followed by Aromatase Inhibitors , 2006, Cancer investigation.
[26] P. Lønning,et al. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[27] D. Ziegler,et al. Clinical use of aromatase inhibitors (AI) in premenopausal women , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[28] N. Skakkebæk,et al. Inhibin A and B as markers of menopause: a five‐year prospective longitudinal study of hormonal changes during the menopausal transition , 2005, Acta obstetricia et gynecologica Scandinavica.
[29] A. Goldhirsch,et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] D. Seifer,et al. Dimeric inhibin: a direct marker of ovarian aging. , 1998, Fertility and sterility.
[31] M. Cobleigh,et al. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Sherry Sherman,et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. , 2012, Fertility and sterility.
[33] I. Henderson. Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer: Swain SM, Jeong J-H, Geyer CE Jr, et al (Washington Cancer Inst at Washington Hosp Ctr, DC; Univ of Pittsburgh, PA; et al) N Engl J Med 362:2053-2065, 2010§ , 2011 .
[34] A. Goldhirsch,et al. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause , 2011, Breast Cancer Research and Treatment.
[35] A. Buzdar. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] C. Welt,et al. Female reproductive aging is marked by decreased secretion of dimeric inhibin. , 1999, The Journal of clinical endocrinology and metabolism.